TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
AIMS: Drug-eluting stents (DESs) have shown to be effective in reducing in-stent restenosis, although data relating to long-term experience in treating more complex lesion subsets are limited. In order to assess the long-term safety and clinical efficacy of the polymer-based moderate release (MR) p...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2007
|
_version_ | 1797072264479375360 |
---|---|
author | Grube, E Dawkins, K Guagliumi, G Banning, A Zmudka, K Colombo, A Thuesen, L Hauptman, K Marco, J Wijns, W Popma, J Buellesfeld, L Koglin, J Russell, M |
author_facet | Grube, E Dawkins, K Guagliumi, G Banning, A Zmudka, K Colombo, A Thuesen, L Hauptman, K Marco, J Wijns, W Popma, J Buellesfeld, L Koglin, J Russell, M |
author_sort | Grube, E |
collection | OXFORD |
description | AIMS: Drug-eluting stents (DESs) have shown to be effective in reducing in-stent restenosis, although data relating to long-term experience in treating more complex lesion subsets are limited. In order to assess the long-term safety and clinical efficacy of the polymer-based moderate release (MR) paclitaxel-eluting TAXUS MR stent in treatment of complex lesion subsets, we evaluated the 2-year follow-up of TAXUS VI. METHOD AND RESULTS: TAXUS VI was a randomized multi-centre study enrolling 446 patients with complex lesions, including small vessels in 28% of patients and a mean lesion length of 20.6 mm. At 9-month follow-up, the use of the TAXUS MR stent was highly effective, resulting in a significant 53% reduction of the target vessel revascularization (TVR) rate (primary endpoint) from 19.4% in the control group to 9.1% in the TAXUS group (P = 0.0027). Clinical follow-up at 2 years post-stenting was available in 98.6% of the TAXUS group and 95.6% of the control group. The incidence of major adverse cardiac event at 1- and 2-year follow-up was 16.4% and 21.3% in the TAXUS group when compared with 22.5 and 25.1% in the control group, respectively. A significant difference in TVR was maintained at 2-year follow-up (TAXUS 13.9%; control 21.9%; P = 0.0335). The cumulative 1- and 2-year survival rates free from TVR were, respectively, 91.7 and 90.3% in the TAXUS group vs. 80.0 and 79.0% in the control group (log-rank P < 0.001). The number of patients required to be treated with a TAXUS stent to prevent one re-percutaneous coronary intervention at 2 years was 12.5. CONCLUSION: Treatment of complex coronary lesions with the polymer-based MR paclitaxel-eluting TAXUS MR stent is associated with a sustained clinical benefit and low rates of TVR up to 2 years after device implantation. |
first_indexed | 2024-03-06T23:05:15Z |
format | Journal article |
id | oxford-uuid:638da94b-b95f-4827-8fca-c4df841496fd |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-06T23:05:15Z |
publishDate | 2007 |
record_format | dspace |
spelling | oxford-uuid:638da94b-b95f-4827-8fca-c4df841496fd2022-03-26T18:13:44ZTAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:638da94b-b95f-4827-8fca-c4df841496fdEnglishSymplectic Elements at Oxford2007Grube, EDawkins, KGuagliumi, GBanning, AZmudka, KColombo, AThuesen, LHauptman, KMarco, JWijns, WPopma, JBuellesfeld, LKoglin, JRussell, M AIMS: Drug-eluting stents (DESs) have shown to be effective in reducing in-stent restenosis, although data relating to long-term experience in treating more complex lesion subsets are limited. In order to assess the long-term safety and clinical efficacy of the polymer-based moderate release (MR) paclitaxel-eluting TAXUS MR stent in treatment of complex lesion subsets, we evaluated the 2-year follow-up of TAXUS VI. METHOD AND RESULTS: TAXUS VI was a randomized multi-centre study enrolling 446 patients with complex lesions, including small vessels in 28% of patients and a mean lesion length of 20.6 mm. At 9-month follow-up, the use of the TAXUS MR stent was highly effective, resulting in a significant 53% reduction of the target vessel revascularization (TVR) rate (primary endpoint) from 19.4% in the control group to 9.1% in the TAXUS group (P = 0.0027). Clinical follow-up at 2 years post-stenting was available in 98.6% of the TAXUS group and 95.6% of the control group. The incidence of major adverse cardiac event at 1- and 2-year follow-up was 16.4% and 21.3% in the TAXUS group when compared with 22.5 and 25.1% in the control group, respectively. A significant difference in TVR was maintained at 2-year follow-up (TAXUS 13.9%; control 21.9%; P = 0.0335). The cumulative 1- and 2-year survival rates free from TVR were, respectively, 91.7 and 90.3% in the TAXUS group vs. 80.0 and 79.0% in the control group (log-rank P < 0.001). The number of patients required to be treated with a TAXUS stent to prevent one re-percutaneous coronary intervention at 2 years was 12.5. CONCLUSION: Treatment of complex coronary lesions with the polymer-based MR paclitaxel-eluting TAXUS MR stent is associated with a sustained clinical benefit and low rates of TVR up to 2 years after device implantation. |
spellingShingle | Grube, E Dawkins, K Guagliumi, G Banning, A Zmudka, K Colombo, A Thuesen, L Hauptman, K Marco, J Wijns, W Popma, J Buellesfeld, L Koglin, J Russell, M TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. |
title | TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. |
title_full | TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. |
title_fullStr | TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. |
title_full_unstemmed | TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. |
title_short | TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. |
title_sort | taxus vi 2 year follow up randomized comparison of polymer based paclitaxel eluting with bare metal stents for treatment of long complex lesions |
work_keys_str_mv | AT grubee taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT dawkinsk taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT guagliumig taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT banninga taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT zmudkak taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT colomboa taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT thuesenl taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT hauptmank taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT marcoj taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT wijnsw taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT popmaj taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT buellesfeldl taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT koglinj taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions AT russellm taxusvi2yearfollowuprandomizedcomparisonofpolymerbasedpaclitaxelelutingwithbaremetalstentsfortreatmentoflongcomplexlesions |